Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR TTM) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
We believe the next revolution in cancer treatment is the development of AlloCAR TTM therapies engineered from the T cells of healthy donors. These off-the-shelf CAR T therapies enhanced by gene editing could be the next most important breakthrough in the field. Our mission is to catalyze this immune cell therapy approach and deliver AlloCARsTM to patients with hematologic cancers and solid tumors to make a difference in their lives.
Official site: https://www.allogene.com/